Protara Therapeutics to Participate in Upcoming Investor Conferences
Wednesday, March 1, 2023 1 min read
Key Takeaway: Protara Therapeutics, Inc. announced its participation in the upcoming Cowen 43rd Annual Health Care Conference on March 8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. Management will engage with investors through a fireside chat and a corporate presentation, respectively. The company is dedicated to developing innovative therapies aimed at treating cancer and rare diseases, with key programs like TARA-002 and IV Choline Chloride.
Market Sentiment Analysis
POSITIVE FACTORS
Protara Therapeutics is actively participating in multiple investor conferences.
The company is focusing on transformative therapies for cancer and rare diseases.
Protara's portfolio includes promising investigational therapies.
Full Press Release Details
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:
Cowen 43rd Annual Health Care Conference. A fireside chat will take place on Wednesday, March 8, 2023 at 9:50 am ET in Boston, MA.
Oppenheimer 33rd Annual Healthcare Conference. A corporate presentation will take place virtually on Tuesday, March 14, 2023 at 1:20 pm ET.
A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.